Jan 30 (Reuters) – Novo Nordisk’s Wegovy pill hits over 26,000 U.S. prescriptions in the second full week after its launch, IQVIA data shared by an analyst on Friday showed.
Investors are closely watching prescription data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lilly in a competitive weight-loss market.
The Wegovy pill was prescribed 26,109 times for the week ended January 23, suggesting the launch of the oral drug is very strong, Barclays analysts wrote in a note.
The pill hit 3,071 U.S. prescriptions in the first four days after its launch on January 5, and over 18000 prescriptions in the week ended January 16.
(Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore)